Also found in: Medical.
JAK2Janus-Activated Kinase 2
JAK2Janus Family Kinase-2 (endocrinology)
JAK2Just Another Kinase 2 (now Janus-Activated Kinase 2; biochemistry)
References in periodicals archive ?
Pacritinib is an investigational oral multikinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R, which are kinases found to be involved in the growth and spread of myelofibrosis and other blood-related cancers such as acute myeloid leukemia (AML).
About Baricitinib Baricitinib is the only once-daily oral selective JAK1 and JAK2 inhibitor currently in late-stage clinical studies for inflammatory and autoimmune diseases.
The blots were stripped via incubation in stripping solution for 30 min at 55[degrees]C, blocked and re-probed for JAK2 and STAT5.
A specific JAK2 inhibitor is now available, but it currently is not approved for use in PV patients.
Although JAK2 and MPL mutations are not supposed to be primary causes of MPN, but rather secondary events associated with disease progression in a still unknown way, the acquisition of one of these gain-of-function mutations seems to be necessary for the development of the myeloproliferative phenotype.
There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.
to treat adult patients with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma and tosedostat gearing up to initiate a pivotal phase 3 trial in relapsed or refractory acute myeloid leukemia/myelodysplastic syndromes ("MDS") later this year, the agreement to acquire pacritinib, a highly selective JAK2 inhibitor, rounds out our novel late stage oncology drug portfolio placing us in a select group of biotech companies.
Approximately 50% of patients have been found to have the JAK2 V617F mutation.
Analysis of the JAK2 V617F mutation: Granulocytes were separated from peripheral blood (10 ml) and genomic DNA was extracted using conventional gradient centrifugation technique.
Earlier, JAK2 was only thought to function on the inner surface of cells.